GlassScriptPhysician profile
Aarat Patel
NPI 1528203874
$605,184.04
in general payments reported to CMS, 2019-2025
45 companies · $10K in 2025
The $10K reported for 2025 was more than what 96% of Pediatric Rheumatology providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215K · 2020: $68K · 2021: $49K · 2022: $94K · 2023: $79K · 2024: $88K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $119K · Honoraria: $34K · Consulting Fee: $10K · Food and Beverage: $7,321 · Travel and Lodging: $6,771 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $118,958.00 |
| Honoraria | $34,387.50 |
| Consulting Fee | $10,125.00 |
| Food and Beverage | $7,321.47 |
| Travel and Lodging | $6,771.46 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $104,071.76 | 2019-2024 | |
| Celgene Corporation | $99,433.64 | 2019 | |
| Amgen INC. | $82,637.19 | 2019-2025 | Krystexxa, Otezla, Enbrel |
| Mallinckrodt Enterprises LLC | $64,827.13 | 2019 | |
| Mallinckrodt Hospital Products INC. | $64,002.57 | 2020-2024 | Acthar |
| Lilly USA, LLC | $53,685.15 | 2019-2023 | Taltz |
| Glaxosmithkline, LLC. | $33,387.43 | 2019-2024 | Benlysta |
| Horizon Therapeutics Plc | $30,518.55 | 2019-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $21,976.48 | 2022-2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $20,272.03 | 2019-2024 | |
| Pfizer INC. | $15,758.07 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $5,639.39 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $3,736.62 | 2019 | |
| Gilead Sciences, INC. | $1,313.43 | 2019-2020 | |
| Janssen Biotech, INC. | $831.02 | 2019-2023 | Tremfya, Simponi Aria, Simponi |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aarat Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.